European Association for the Study of Diabetes (EASD) Annual Meeting 2025

The use of tirzepatide in a real-world setting demonstrates a favourable safety profile and results in weight loss, lower insulin requirements, and better glycaemic measurements among patients with type 1 diabetes (T1D), as shown in a study presented at EASD 2025.

An inverse association exists between self-reported physical activity (PA) and the risk of major adverse cardiac events (MACE) and all-cause mortality among individuals with type 2 diabetes (T2D) and no previous cardiovascular disease (CVD), suggests a study presented at EASD 2025.

A large study from Denmark presented at EASD 2025 suggests that overweight and obesity may protect against death.

The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).